C-terminal peptides of p53 molecules enhance radiation-induced apoptosis in human mutant p53 cancer cells

Apoptosis

Volumn 9, Issue 5, 2004, Pages 591-597

  Ohnishi, K ^a   Inaba, H ^a   Yasumoto, J ^a   Yuki, K ^a   Takahashi, A ^a   Ohnishi, T ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

apoptosis; caspase 3; p53; PARP; peptide

Indexed keywords

CASPASE 3; HOE 33342; PEPTIDE DERIVATIVE; PROTEIN P53;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL MUTANT; CONTROLLED STUDY; DNA BINDING; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN TARGETING; STAINING; X IRRADIATION;

AMINO ACID SEQUENCE; APOPTOSIS; CELL LINE, TUMOR; CONSENSUS SEQUENCE; GENES, P53; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PEPTIDE FRAGMENTS; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS;

EID: 4344698422     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APPT.0000038044.40337.35     Document Type: Article

References (50)

1. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-223.
2. Dulic V, Kaufmann WK, Wilson SJ, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013-1023.
3. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
4. Harima Y, Harima K, Shikata N, et al. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998; 124: 503-510.
5. Harima Y, Nagata K, Harima K, et al. Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIb cervical carcinoma. Cancer 2000; 88: 131-137.
6. Bargonetti J, Friedman PN, Kern SE, et al. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 1991; 65: 1083-1091.
7. Kern SE, Kinzler KW, Bruskin A, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252: 1708-1711.
8. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991; 253: 49-53.
9. Jia LQ, Osada M, Ishioka C, et al. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 1997; 19: 243-253.
10. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287-2291.
11. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
12. Spitz FR, Nguyen D, Skibber JM, et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996; 16: 3415-3422.
13. Fujiwara T, Cai DW, Georges RN, et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-1462.
14. Roth JA. Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wild-type (normal) p53. Hum Gene Ther 1996; 7: 861-874.
15. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985-991.
16. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat Med 1999; 5: 1256-1263.
17. Cowsill C, Southgate TD, Morrissey G, et al. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidme kinase: Reduced cytotoxicity of a truncated HSV1-TK. Gene Ther 2000; 7: 679-685.
18. Bargonetti J, Manfredi JJ, Chen X, et al. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 1993; 7: 2565-2574.
19. Halazonetis TD, Kandil AN. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 1993; 12: 5057-5064.
20. Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994; 265: 346-355.
21. Hupp TR, Meek DW, Midgley CA, et al. Regulation of the specific DNA binding function of p53. Cell 1992; 71: 875-886.
22. Hupp TR, Lane DP. Allosteric activation of latent p53 tetramers. Curr Biol 1994; 4: 865-875.
23. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995; 83: 237-245.
24. Hupp TR, Meek DW, Midgley CA, et al. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res 1993; 21: 3167-3174.
25. Niewolik D, Vojtesek B, Kovarik J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 1995; 10: 881-890.
26. Abarzua P, LoSardo JE, Gubler ML, et al. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 1996; 13: 2477-2482.
27. Abarzua P, LoSardo JE, Gubler ML, et al. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res 1995; 55: 3490-3494.
28. Selivanova G, Iotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997; 3: 632-638.
29. Kim AL, Raffo AJ, Brandt-Rauf PW, et al. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 1999; 274: 4924-34931.
30. Selivanova G, Ryabchenko L, Jansson E, et al. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 1999; 19: 3395-3402.
31. Rosse T, Olivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome C. Nature 1998; 391: 496-499.
32. Stennicke HR, Salvesen GS. Properties of the caspases. Biochem Biophys Acta 1998; 1387: 17-31.
33. Fujita N, Tsuruo T. Involvement of Bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis. Biochem Biophys Res Commun 1998; 246: 484-488.
34. Kaufmann SH, Desnoyers S, Ottaviano Y, et al. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976-3985.
35. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 27: 293-299.
36. Kern SE, Pietenpol JA, Thiagalingam S, et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827-830.
37. Unger T, Nau MM, Segal S, et al. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 1992; 11: 1383-1390.
38. Delphin C, Baudier J. The protein kinase C activator, phorbol ester, cooperates with the wild-type p53 species of Ras-transformed embryo fibroblasts growth arrest. J Biol Chem 1994; 269: 29579-29587.
39. Takenaka I, Morin F, Seizinger BR, et al. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 1995; 270: 5405-5411.
40. Waterman JL, Shenk JL, Halazonetis TD. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J 1995; 14: 512-519.
41. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22: 7486-7495.
42. Okamura S, Arakawa H, Tanaka T, et al. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001; 8: 85-94.
43. Oda K, Arakawa H, Tanaka T, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000; 102: 849-862.
44. Ohnishi K, Ota I, Takahashi A, et al. Glycerol restores p53-dependent radiosensitivity of human head and neck cancer cells bearing mutant p53. Brit J Cancer 2000; 83: 1735-1739.
45. Issaeva N, Friedler A, Bozko P, et al. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci 2003; 100: 13303-13307.
46. Peng Y, Li C, Chen L, et al. Rescue of mutant p53 transcription function by ellipticine. Oncogene 2003; 22: 4478-4487.
47. Foster BA, Coffey HA, Morin MJ, et al. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286: 2507-2510.
48. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288.
49. Ohnishi T, Ohnishi K, Wang X, et al. Restoration of mutant TP53 to normal TP53 function by glycerol as a chemical chaperone. Radiat Res 1999; 151: 498-500.
50. Ohnishi K, Wang X, Takahashi A, et al. Contribution of protein kinase C to p53 dependent WAF1 induction pathway after heat treatment in human glioblastoma cell lines. Exp Cell Res 1998; 238: 399-406.